Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit

2 years ago

HAMILTON, BERMUDA , Jan. 08, 2024 (GLOBE NEWSWIRE) -- Altamira Therapeutics to Present at 3rd Annual mRNA-Based Therapeutics Summit Altamira’s…

Stereotaxis Announces First Patients Successfully Treated Using MAGiC Ablation Catheter

2 years ago

ST. LOUIS, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer in surgical robotics for minimally invasive endovascular…

Yield10 Bioscience Files Request for Regulatory Status Review with USDA-APHIS for Camelina Designed to Produce the EPA and DHA Components of Omega-3 Oil

2 years ago

Advanced technology enables the land-based production of omega-3 (EPA+DHA) in Camelina potentially representing a novel solution to the market need…

Standard BioTools Announces Preliminary Fourth Quarter and Full Year 2023 Revenue

2 years ago

Achieving scale with pro forma full year 2023 revenue of approximately $192 millionSOUTH SAN FRANCISCO, Calif., Jan. 08, 2024 (GLOBE…

Evaxion Announces Plan to Implement ADS Ratio Change

2 years ago

COPENHAGEN, Denmark, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage TechBio…

USAN Approves Generic Name “Ruxoprubart” for NM8074, an Antibody Therapy focused on Complement-Mediated Diseases

2 years ago

The USAN Council has officially adopted "Ruxoprubart (Ruk”soe proo' bart)" as the generic name for NM8074, marking a significant milestone…

Artelo Biosciences Announces Selection of Worldwide Clinical Trials as Clinical Research Organization to Support First-in-Human Study of ART26.12

2 years ago

SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Artelo Biosciences, Inc. (Nasdaq: ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling…

Veru Submits IND Application to FDA for the Development of Enobosarm to Prevent Muscle Loss While Augmenting Fat Loss in Combination with GLP-1 Drugs for Weight Loss

2 years ago

MIAMI, FL, Jan. 08, 2024 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

Neuronetics Reports Preliminary Fourth Quarter and Fiscal Year 2023 Financial Results

2 years ago

MALVERN, Pa., Jan. 08, 2024 (GLOBE NEWSWIRE) -- Neuronetics, Inc. (NASDAQ: STIM) (the “Company” or “Neuronetics”) a commercial stage medical technology…

NightHawk Biosciences Announces Planned Name Change to Scorpius Holdings, Reflecting Successful Transition to a Large Molecule Biomanufacturing CDMO

2 years ago

Announces senior leadership appointments to further support client programs and growing sales pipelineDURHAM, N.C., Jan. 08, 2024 (GLOBE NEWSWIRE) --…